Series A AI companies in London

Companies building AI products, foundation models, and applied ML platforms. Filtered to Series A-stage companies headquartered in London.

Edit the query above, or pick a refinement. 500 free credits on sign-up, no card needed.

Built from a search like: “Top Series A AI companies in London”

Ranked by current headcount across Series A AI companies in London. Refreshed daily.

1
Google DeepMind· London, England, United Kingdom
We’re a team of scientists, engineers, machine learning experts and more, working together to advance the state of the art in artificial intelligence. We use our technologies for widespread public benefit and scientific discovery, and collaborate with others on critical challenges, ensuring safety and ethics are the highest priority.Our long term aim is to solve intelligence, developing more general and capable problem-solving systems, known as artificial general intelligence (AGI). Guided by safety and ethics, this invention could help society find answers to some of the world’s most pressing and fundamental scientific challenges. We have a track record of breakthroughs in fundamental AI research, published in journals like Nature, Science, and more.Our programs have learned to diagnose eye diseases as effectively as the world’s top doctors, to save 30% of the energy used to keep data centres cool, and to predict the complex 3D shapes of proteins - which could one day transform how drugs are invented.
- Series A
- 10.3k employees
- Founded 2010
2
IMU Biosciences· London, England, United Kingdom
Mapping the immune system in unprecedented detail and scale. IMU’s discovery platform is building a new understanding of the immune system across health and disease, through next generation high resolution, systems-level immune profiling with AI & ML analytics.
- Series A
- 78 employees
- Founded 2019
3
Verdiva Bio· London, England, United Kingdom
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.For more information, please visit www.verdivabio.com.
- Series A
- 76 employees
- Founded 2024
Live search
This list is a starting point
I can run a natural-language search across LinkedIn, GitHub, and the open web. Fire one of these, or edit the box up top to match exactly who you're after.
- Engineers at top Series A AI companies in LondonRun
- Founders of Series A AI companies in LondonRun
500 free credits on sign-up, no card needed.
4
National Cancer Research Institute (NCRI)· London, England, United Kingdom
The National Cancer Research Institute (NCRI) is a UK-wide partnership between cancer research funders, which promotes collaboration in the field. Our role is to promote co-operation in cancer research for the benefit of patients, the public and the scientific community. We focus on challenging areas of research where partners can achieve greater progress by working together.What we do:• We run the annual NCRI Cancer Conference, which is the leading meeting in the UK for showcasing cancer research. It covers a spectrum of basic, clinical, translational and patient-focused research, and attracts around 2000 delegates.• We identify areas of need in UK cancer research and set up collaborative initiatives to help address them.• We collect information every year on how much is being spent on cancer research in the UK by NCRI partners, to inform funding strategies and identify areas of need and opportunity. What we don’t do:• We don’t fund research – each of our partners does this directly through a variety of funding streams.• We don’t lobby – we work mainly by promoting coordination, collaboration and communication.
- Series A
- 75 employees
- Founded 2001
5
Alchemab Therapeutics Ltd· London, England, United Kingdom
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
- Series A
- 72 employees
- Founded 2019

6
Portal Biotech· London, England, United Kingdom
Proteins are at the heart of every biological process, yet today’s tools still leave major blind spots. At Portal Biotech, we're developing the first platform capable of sequencing entire proteins at the single-molecule level, replacing fragmented views with a complete picture. We want to empower scientists to understand proteins in depth and in real time, enabling faster drug discovery, more accurate diagnostics, and stronger pandemic readiness. Portal Biotech was founded by DNA-sequencing veterans, leveraging machine-learning algorithms and building on decades of in-house expertise in nanopore technology. By analysing full-length protein molecules at the single-molecule level, our platform delivers rapid, real-time information on protein identity, abundance, and structure. Those insights open frontiers in drug discovery, diagnostics, and fundamental research, helping scientists and clinicians to better understand human health and disease.We’re looking for sharp minds to help bring this vision to life.
- Series A
- 62 employees
- Founded 2021
7
Engitix Therapeutics· London, England, United Kingdom
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours.Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
- Series A
- 61 employees
- Founded 2016
8
Shellworks· Greater London, England, United Kingdom
Shellworks is a design-led techbio company that creates uncompromising, compostable packaging solutions made from naturally-derived materials. Our first material is called Vivomer, a bio-based, vegan and home compostable alternative to plastic. Working in collaboration with nature, Vivomer is made and unmade by microbes.
- Series A
- 48 employees
- Founded 2019
9
Mytos· London, England, United Kingdom
Mytos automates production of stem cell-derived therapies - enabling them to scale to millions of patients at low cost. Our custom iDEM robotics platform powers our automated CDMO.Our announced partnerships include neurons for treating Parkinson's, bone for bone repair, corneal cells for blindness, and auditory neurons for hearing loss (and we have more to announce). Cells produced on our iDEM platform will be going into patients by 2027.Mytos has raised over $24m from leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. We're hiring now - visit our website to see open positions
- Series A
- 48 employees
- Founded 2016
10
Peptone· London, England, United Kingdom
Peptone is a therapeutics company that uses AI and an experimental physics product engine to design small molecules targeting the 6,200 intrinsically disordered human proteins that Alpha Fold 3 cannot model.
- Series A
- 45 employees
- Founded 2018

Reveal 22 more·500 free credits, no card

Find engineers at Series A AI companies in London

Searching for “engineers at top Series A AI companies in London” surfaces this slice of the market. The list above ranks AI companies headquartered in London whose latest disclosed round is Series A, by current headcount, drawn from public LinkedIn and Crunchbase records. With 27 matching companies in Refolk’s index, this is a tight read on where the AI talent in London is heating up.

Three filters at once narrows the field hard. The companies that survive all three - Series A, AI, in London - are usually the most targeted recruiting pool a hiring manager can ask for. Senior engineers, founding designers, and product leads here are about to become AI’s next operators and angel investors.

Refolk converts this list into a live search. Ask for “senior engineers at Series A AI companies in London hiring” or “founders of Series A AI companies in London who left in the last year” and Refolk returns a ranked shortlist with the evidence behind each match.

How this list is built

Refolk pulled AI companies headquartered in London whose latest disclosed funding round is Series A from public LinkedIn and Crunchbase records, ranked them by current employee count, and kept those with at least 3 employees. The list refreshes once a day.

Last refreshed: Wed, 05 Aug 2026 11:09:58 GMT

Need an even more specific search?

Refolk runs natural-language searches across LinkedIn, GitHub, and the open web. Try one of these:

Related lists

See all company lists.

Slice this list a different way

Common questions

How is this ranking built?

The list draws on the public company graph - headcount and growth signals, funding history, and recency. The criteria chips at the top show exactly which filters produced it, and the methodology section explains the ranking.

How fresh is the data?

The underlying index updates continuously and this page re-renders at least daily. Last refreshed: Wed, 05 Aug 2026 11:09:58 GMT.

Can I get the full list of 27 companies?

Yes. This page shows the top of the ranking; sign up and I'll run the search live for the complete, current list. You start with 500 free credits, no card required.

Can I find the people inside these companies?

Yes. Ask in plain English - for example "engineering leaders at these companies who joined in the last year" - and I return the specific people, with context on each.

This list is a starting point